Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.
Abstract: The present invention involves a pharmaceutical formulation comprising a liposome having a therapeutically effective concentration of an aromatic polyene macrolide antibiotic. The aromatic polyene macrolide antibiotic usable in the practice of the present invention is selected from the group consisting of candicidin, hamycin, aurefungin, ascosin, ayfattin, azacolutin, DJ400-B, trichomycin, levorin, heptamycin, candimycin or perimycin. The most preferred aromatic polyene macrolide antibiotic is candicidin. An important aspect of the present invention is a method for treating disseminated fungal infection in an animal comprising administering to an animal such as a human a pharmaceutical formulation comprising a liposome having a therapeutically effective amount of aromatic polyene macrolide antibiotic as described above.
Type:
Grant
Filed:
November 10, 1988
Date of Patent:
March 12, 1991
Assignee:
Board of Regents, The University of Texas System
Inventors:
Elias J. Anaissie, Georgios Samonis, Hans Krause, Gerald P. Bodey
Abstract: This invention provides compositions comprising a physiologically-active agent and a compound having the structural formula ##STR1## Wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --Ch.sub.3, ##STR2## wherein R" is H or halogen, in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.
Type:
Grant
Filed:
April 19, 1989
Date of Patent:
February 12, 1991
Assignee:
Whitby Research, Inc.
Inventors:
Gevork Minaskanian, James Peck, Eric L. Nelson
Abstract: A method of treating, by intramammary infusion of liposomes, Brucella spp. infections in an animal by administration of a therapeutically effective amount of aminoglycoside in liposome form, also being a method of administering a therapeutic agent in liposome form to a proximal mammary lymph node or mammary tissue of an animal.
Type:
Grant
Filed:
August 18, 1987
Date of Patent:
January 1, 1991
Assignee:
The Liposome Company, Inc.
Inventors:
Mircea Popescu, Christine E. Swenson, Sterling C. Johnson, Robert P. Lenk
Abstract: Skin care cosmetic formulations which include a cellulosic polymer/solvent system capable of dispersing thin, substantive films on the skin are disclosed.
Type:
Grant
Filed:
December 16, 1985
Date of Patent:
October 16, 1990
Assignee:
Carter-Wallace Inc.
Inventors:
Robert G. Fourman, Richard P. Dixon, Hans Breuer
Abstract: Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of the human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.
Type:
Grant
Filed:
May 23, 1988
Date of Patent:
September 25, 1990
Assignees:
Beth Israel Hospital Assn., The Brigham and Womens Hospital, Inc.
Inventors:
Martin C. Carey, Alan C. Moses, Jeffrey S. Flier
Abstract: A method of selectively enhancing efficacy of gentamicin, when used in the treatment of Mycobacterium avium Complex (MAC), by intravenous administration of the drug in liposomal form. Gentamicin-liposomes are comparable to amikacinliposomes in activity against MAC infection in the bloodstream and substantially more effective against MAC infection residing in liver and spleen.
Abstract: The present invention involves a process for producing fine powder suitable for the preparation of antifungal polyene microlide-containing liposomes upon suspension in an aqueous solution. This process comprises the following steps. Quantities of polyene macrolide and phospholipids are dissolved respectively in a first solvent and a second solvent to form a first solution and a second solution. The first solution and the second solution are mixed in a desired ratio to form a mixture. The first solvent and the second solvent are then removed from the mixture, for example by evaporation, to form a residue. The residue is then dissolved in a third solvent comprising tertiary butanol and methylene chloride to form a third solution. The third solvent is then removed from the third solution to form a remnant. The remnant is then dissolved in a solvent consisting essentially of tertiary butanol to form a fourth solution. The fourth solution is then filtered through a filter having orifices of between about 0.
Type:
Grant
Filed:
October 16, 1987
Date of Patent:
August 21, 1990
Assignee:
Board of Regents, The University of Texas System
Abstract: The invention provides a method of producing a water-soluble complex comprising a water-insoluble drug and a phospholipid, comprising the steps of (1) dissolving a water-insoluble drug and a phospholipid in an organic solvent, (2) removing the solvent to leave behind a drug-containing phospholipid film, (3) suspending the resulting film in an aqueous solution, (4) ultrasonicating the film, (5) centrifuging the resulting suspension, and (6) recovering the lowermost layer of the resulting sediment to yield the water-soluble complex. The above complex can be administered parenterally as well as by the oral and other routes, and is so rich in the drug component that a remarkably increased drug activity can be realized.
Abstract: Novel hydrophilic protein or polypeptide microspheres prepared by dispersing an aqueous solution or dispersion of protein or polypeptide in an organic solvent solution of a high molecular weight polymer to form a stabilized dispersion of microspheres and cross-linking said microspheres with a polyfunctional cross-linking agent.
Type:
Grant
Filed:
February 4, 1986
Date of Patent:
June 9, 1987
Assignee:
University of Florida
Inventors:
Eugene P. Goldberg, William E. Longo, Hiroo Iwata
Abstract: Method for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising liposome-encapsulated Amphotericin B, said liposome being comprised of lipids other than sterols.
Type:
Grant
Filed:
April 16, 1984
Date of Patent:
May 5, 1987
Assignee:
The Board of Regents of the University of Texas System
Inventors:
Gabriel Lopez-Berestein, Victor Fainstein, Evan M. Hersh, Roy L. Hopfer, Rudolph L. Juliano, Kapil Mehta, Reeta Mehta
Abstract: The invention relates to a synergistic antibiotic composition useful for the treatment of respiratory, gastrointestinal or urinary infections and septicaemia of domestic animals. The composition comprises tiamulin hydrogen fumarate and an aminoglycoside antibiotic or a pharmaceutically acceptable salt thereof in a weight ratio of 5:1 to 1:5. The active components are admixed or diluted with a carrier, used in veterinary therapy, in a weight ratio of 1:1 to 1:50 and formulated for oral or parenteral application.
Type:
Grant
Filed:
March 28, 1985
Date of Patent:
March 17, 1987
Assignee:
Patentbureau Danubia
Inventors:
Ferenc Simon, Attila Romvary, Janos Varga, Laszlo Bozzay, Edit Bruckner nee Gabor
Abstract: Aminoglycosides and aminoglycoside-aminocyclitols which have been oxygen-radical activated show a broad spectrum of antibacterial activity. The activated compounds are able to penetrate the cell membranes of bacteria and show substantially enhanced activity as compared to the parent unactivated compound.
Abstract: The method disclosed herein is applicable in traumatology for treatment of infected false joints, as well as some forms of osteomyelitis.The method consists in administering medicinal solutions to at least two areas in the locus of infection of the bone tissue, one of said solutions Medicinal Solution No. 1 having the following weight percentage composition:______________________________________ monobasic calcium phosphate 0.0375 to 0.15 Ca(H.sub.2 PO.sub.4).sub.2.H.sub.2 O calcium chloride CaCl.sub.2 0.05 to 0.2 calcium hydroxide 1.5 to 6.0 novocain 0.09 to 0.36 sodium chloride 0.216 to 0.864 antibiotic 1.65 to 6.6 water to make up 100 percent, ______________________________________the pH value of said solution being within 6.0 and 6.4, while administered to the other area of said locus of infection is an antiseptic having the pH value within 7.5 and 8.1, both of said solutions being administered dripwise continuously for 5 to 14 days per treatment course.
Type:
Grant
Filed:
October 22, 1984
Date of Patent:
July 29, 1986
Assignee:
Nauchno-Issledovatelskaya Laboratoria Metalloosteosinteza S Klinikoi Imeni A, Seppo
Inventors:
Khelgi S. Veerme, Arnold I. Seppo, deceased
Abstract: A granulation method involving polysaccharide gelling agents, e.g., alginic acid, and a metal salt, e.g., magnesium salt is developed for the stabilization of heat and/or moisture sensitive drugs or food supplements such as Efrotomycin, avermectins, milbemycins, mocimycin and other drugs. It has been found that the granules so obtained can be incorporated into various formulations without substantial decomposition.
Type:
Grant
Filed:
February 1, 1983
Date of Patent:
July 1, 1986
Assignee:
Merck Sharp & Dohme
Inventors:
Howard C. Maxfield, Anthony J. Phillips, Richard J. Yarwood
Abstract: This invention relates to penicillanic acid derviatives of the formula I ##STR1## in which X stands for chlorine, bromine or iodine, to pharmaceutically acceptable, non-toxic salts of the compounds of formula I, to pharmaceutically acceptable, easily hydrolyzable esters thereof, including salts of such esters, to pharmaceutical compositions containing the compounds of the invention and dosage units thereof, to methods for the preparation of the compounds of the invention, and to methods of using the said new compounds in the human and veterinary therapy.The 6.beta.-halopenicillanic acids of formula I are potent inhibitors of .beta.-lactamases from a variety of gram-positive and gram-negative bacteria, making the 6.beta.-halopenicillanic acids as well as their salts and easily hydrolyzable esters valuable in human and veterinary medicine.